Liquidia Shares Plunge 48% After Adverse Patent Ruling; Options Market Sees Speculative Surge

Shares of Liquidia Corp. (LQDA) plunged by nearly 50% on Wednesday after a U.S. District Court ruled the company infringed on key patents held by rival United Therapeutics (UTHR), leading to multiple trading halts and a surge in speculative options activity.

Court Rules Against Liquidia

A U.S. District Court in Delaware found that Liquidia's flagship drug, YUTREPIA, infringed upon two claims of United Therapeutics’ Patent No. 11,826,327. The patent covers the use of inhaled treprostinil for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Following the news, Liquidia's stock fell approximately 48% to trade around $36.87. The sharp decline triggered several trading halts by Nasdaq. In a direct reflection of the zero-sum nature of patent litigation, shares of United Therapeutics rose on the same news.

Commercial Implications and Company Response

The PH-ILD indication is a critical growth driver for Liquidia, representing roughly half of YUTREPIA’s total addressable market. In a significant concession, Liquidia announced it will submit a supplement to the FDA to have the PH-ILD indication removed from the drug's label.

Ad

United Therapeutics is also seeking injunctive relief, which could potentially impose restrictions beyond the label change. Liquidia CEO Roger Jeffs confirmed the company will pursue all available appellate options, setting the stage for a prolonged legal battle.

Options Market Signals Volatility

The court's decision sparked a flurry of activity in the options market, with total volume reaching 33,608 contracts by mid-afternoon. In a counterintuitive move for a stock down sharply, call options outpaced put options, with a call/put ratio of approximately 1.51.

This activity was concentrated in deep out-of-the-money call strikes, such as the October $75 and December $125 contracts. This pattern suggests traders are not expressing broad bullishness but are instead making highly speculative bets on a sharp recovery if the company's appeal is successful. The market's expectation of future turbulence was also evident as 3-month implied volatility on the stock jumped to 89.44%, signaling that traders are pricing in the potential for large, binary price swings.